Partners

ASX
LCT 0.041   Last updated EOD 10th December 2018
Fact sheet
The following fact sheets provide a summary of our current business and research pipeline.
Register for email updates
Register now to receive our newsletter and updates on LCT’s activities and progress.

Fact sheet

Technology platforms

Our breakthrough encapsulation delivery technology, IMMUPEL™, enables treatments to be delivered without immunosuppression. 

PRINT PAGE print-icon
Register for email updates
Register now to receive our newsletter and updates on LCT’s activities and progress.